tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Aicher L et al. Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. 1997 Biochem. Pharmacol. pmid:9113092
Hikita N et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. 1997 Invest. Ophthalmol. Vis. Sci. pmid:9112986
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Holt DW and Johnston A Tacrolimus quality assessment. 1997 Ther Drug Monit pmid:9108659
Lee JW et al. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. 1997 Ther Drug Monit pmid:9108651
Beals CR et al. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. 1997 Genes Dev. pmid:9106655
Kawamura N et al. Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. 1997 Int. Arch. Allergy Immunol. pmid:9104801
Hess DA et al. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation. 1997 J. Pharmacol. Exp. Ther. pmid:9103542
Mori A et al. IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. 1997 J. Immunol. pmid:9103428
Guérette B et al. Inflammatory damage following first-generation replication-defective adenovirus controlled by anti-LFA-1. 1997 J. Leukoc. Biol. pmid:9103242
Taylor P et al. Conformational polymorphism in peptidic and nonpeptidic drug molecules. 1996 Biopolymers pmid:9101762
Bowman AR et al. The role of testosterone in cyclosporine-induced osteopenia. 1997 J. Bone Miner. Res. pmid:9101372
Blau CA et al. A proliferation switch for genetically modified cells. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9096348
Mori A et al. Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor. 1996 Adv. Exp. Med. Biol. pmid:9095279
Steiner JP et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. 1997 Nat. Med. pmid:9095176
Maurer M et al. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. 1997 Am. J. Pathol. pmid:9094998
Krämer BK and Schweda F Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9093272
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Yasutomi M et al. Evaluation of tetrahydropyranyladriamycin as an immunosuppressant in concordant xenotransplantation. 1997 J. Heart Lung Transplant. pmid:9087871
Wagner K et al. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 1997 J. Heart Lung Transplant. pmid:9087870
Oz HS and Hughes WT Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. 1997 J. Infect. Dis. pmid:9086147
Ohashi Y et al. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. 1997 Bone Marrow Transplant. pmid:9085743
de Paulis A et al. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. 1997 Arthritis Rheum. pmid:9082935
Yoshikawa H et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. 1997 J. Autoimmun. pmid:9080295
Mirza DF et al. Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression. 1997 Lancet pmid:9078209
Ciancio G et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. 1997 Transplantation pmid:9075856
Guo Z et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. 1997 Transplantation pmid:9075844
Grobecker HF et al. Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. 1995 Clin Exp Pharmacol Physiol Suppl pmid:9072458
Victor RG et al. Mechanism of Ca(2+)-dependent inactivation of L-type Ca2+ channels in GH3 cells: direct evidence against dephosphorylation by calcineurin. 1997 J. Membr. Biol. pmid:9070464
Singh N et al. Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. 1997 Clin Transplant pmid:9067698
Guckelberger O et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. 1997 Clin Transplant pmid:9067697
Motamedi H et al. Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK506. 1997 Eur. J. Biochem. pmid:9063448
Göthel SF et al. An internal FK506-binding domain is the catalytic core of the prolyl isomerase activity associated with the Bacillus subtilis trigger factor. 1997 Eur. J. Biochem. pmid:9063446
Garcia-Morales R et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. 1997 J. Clin. Invest. pmid:9062371
Ivery MT and Weiler L Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex. 1997 Bioorg. Med. Chem. pmid:9061187
Bagnis C et al. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. 1997 Am. J. Nephrol. pmid:9057948
Seidel ER and Ragan VL Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture. 1997 Br. J. Pharmacol. pmid:9051292
Steiner JP et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9050897
Wang W et al. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. 1997 Immunity pmid:9047238
Tsuchida Y et al. Limb allografts in rats treated with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies. 1997 J Reconstr Microsurg pmid:9044184
Markus PM et al. Allogeneic hepatocyte transplantation using FK 506. 1997 Jan-Feb Cell Transplant pmid:9040958
Padhi ID et al. Interaction between tacrolimus and erythromycin. 1997 Ther Drug Monit pmid:9029762
Alak AM et al. A highly sensitive enzyme-linked immunosorbent assay for the determination of tacrolimus in atopic dermatitis patients. 1997 Ther Drug Monit pmid:9029754
Iwasaki K et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:9029671
Lo Russo A et al. Cyclosporin A potentiates receptor-activated [Ca2+]c increase. 1997 Jan-May J. Recept. Signal Transduct. Res. pmid:9029487
Budde K et al. Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9024386
Aiko S et al. Effects of cyclosporine or FK506 in chronic colitis. 1997 J. Pharmacol. Exp. Ther. pmid:9023326
[Tacrolimus--a new perspective in kidney transplantation]. 1996 Urologe A pmid:9022401
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333